Detalles de la búsqueda
1.
Cost-effectiveness analysis of ceritinib vs. crizotinib in previously untreated anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in Hong Kong.
Cost Eff Resour Alloc
; 18(1): 50, 2020 Nov 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33292314
2.
Cost-effectiveness analysis of pembrolizumab compared to standard of care as first line treatment for patients with advanced melanoma in Hong Kong.
Cost Eff Resour Alloc
; 18: 2, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-31969794
3.
Immune Checkpoint Inhibitor-induced Enterocolitis.
Clin Gastroenterol Hepatol
; 19(7): e70, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32335134
4.
Crizotinib in the management of advanced-stage non-small-cell lung cancer.
Future Oncol
; 11(5): 735-45, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-25757678
5.
A study of circulating interleukin 10 in prognostication of unresectable hepatocellular carcinoma.
Cancer
; 118(16): 3984-92, 2012 Aug 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-22180222
6.
Prediction of outcome in cancer patients with febrile neutropenia: a prospective validation of the Multinational Association for Supportive Care in Cancer risk index in a Chinese population and comparison with the Talcott model and artificial neural network.
Support Care Cancer
; 19(10): 1625-35, 2011 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-20820815
7.
Prevalence and prognostic impact of comorbidities and peripheral blood indices in sarcomas.
ESMO Open
; 5(6): e001035, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-33214228
8.
What do oncologists need to know about biosimilar products?
Chin J Cancer
; 35(1): 91, 2016 Oct 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-27733189
9.
Detection of ALK rearrangement by immunohistochemistry in lung adenocarcinoma and the identification of a novel EML4-ALK variant.
J Thorac Oncol
; 8(7): 883-91, 2013 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-23625156
Resultados
1 -
9
de 9
1
Próxima >
>>